Board Change • May 19
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Nee Wharry Cope was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 29
Directa Plus plc Announces Resignation of Wesley Clark as Director with Effective 27 April 2026 Directa Plus Plc announced that Wesley Clark has resigned as director of the Company with effective 27 April 2026. New Risk • Apr 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Market cap is less than US$10m (UK£7.05m market cap, or US$9.49m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Announcement • Feb 28
Directa Plus Plc announced that it expects to receive €4 million in funding Directa Plus Plc announced a private placement of non-dilutive potential loan for gross proceeds of €4 million from new lender Nant Capital, LLC on February 27, 2026. Announcement • Jan 07
Directa Plus plc Announces Changes to Its Board, Effective from January 31, 2026 Directa Plus Plc announced that Richard Hickinbotham, Non-Executive Chairman, who would have shortly completed his nine-year tenure with the Group, has informed the Board of his intention to take up a full-time executive role and will step down from the Board on 31 January 2026. Giulio Cesareo will assume the role of Interim plc Chairman with effect from that date. New Risk • Jan 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.7m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 4.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£11.0m market cap, or US$14.8m). Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Non-Executive Director Nee Wharry Cope was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Sep 28
First half 2025 earnings released: €0.016 loss per share (vs €0.037 loss in 1H 2024) First half 2025 results: €0.016 loss per share (improved from €0.037 loss in 1H 2024). Revenue: €3.90m (up 15% from 1H 2024). Net loss: €1.65m (loss narrowed 33% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings. New Risk • Sep 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.7m free cash flow). Earnings have declined by 4.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (UK£10.7m market cap, or US$14.4m). Announcement • Aug 04
Directa Plus Plc to Report First Half, 2025 Results on Sep 24, 2025 Directa Plus Plc announced that they will report first half, 2025 results on Sep 24, 2025 New Risk • Jun 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 4.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risk Market cap is less than US$100m (UK£12.5m market cap, or US$17.0m). Announcement • Jun 07
Directa Plus Plc, Annual General Meeting, Jun 30, 2025 Directa Plus Plc, Annual General Meeting, Jun 30, 2025. Location: 7th floor, 50 broadway, sw1h 0db, london United Kingdom Reported Earnings • Jun 03
Full year 2024 earnings released: €0.06 loss per share (vs €0.058 loss in FY 2023) Full year 2024 results: €0.06 loss per share (further deteriorated from €0.058 loss in FY 2023). Revenue: €6.83m (down 35% from FY 2023). Net loss: €5.14m (loss widened 33% from FY 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. New Risk • Apr 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 3.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£7.57m market cap, or US$9.90m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). New Risk • Feb 21
New major risk - Revenue and earnings growth Earnings have declined by 3.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Earnings have declined by 3.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£6.74m market cap, or US$8.52m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). New Risk • Feb 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£6.27m market cap, or US$7.80m). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Share price has been volatile over the past 3 months (7.2% average weekly change). New Risk • Dec 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.57m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (UK£7.57m market cap, or US$9.63m). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Share price has been volatile over the past 3 months (10% average weekly change). Major Estimate Revision • Oct 02
Consensus revenue estimates decrease by 58% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €17.3m to €7.30m. EPS estimate unchanged from -€0.026 per share at last update. Chemicals industry in the United Kingdom expected to see average net income growth of 44% next year. Consensus price target of UK£1.15 unchanged from last update. Share price fell 28% to UK£0.12 over the past week. Reported Earnings • Sep 27
First half 2024 earnings released: €0.037 loss per share (vs €0.028 loss in 1H 2023) First half 2024 results: €0.037 loss per share (further deteriorated from €0.028 loss in 1H 2023). Revenue: €3.39m (down 26% from 1H 2023). Net loss: €2.47m (loss widened 34% from 1H 2023). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 5.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. New Risk • Sep 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€2.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.0m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (€370k net loss next year). Market cap is less than US$100m (UK£11.7m market cap, or US$15.6m). Announcement • Sep 13
Directa Plus Plc to Report First Half, 2024 Results on Sep 25, 2024 Directa Plus Plc announced that they will report first half, 2024 results on Sep 25, 2024 New Risk • Jul 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 58% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (UK£21.9m market cap, or US$28.1m). Reported Earnings • Jun 27
Full year 2023 earnings released: €0.06 loss per share (vs €0.073 loss in FY 2022) Full year 2023 results: €0.06 loss per share (improved from €0.073 loss in FY 2022). Revenue: €10.9m (flat on FY 2022). Net loss: €3.86m (loss narrowed 20% from FY 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 6.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Price Target Changed • Jun 13
Price target decreased by 20% to UK£1.28 Down from UK£1.59, the current price target is an average from 2 analysts. New target price is 589% above last closing price of UK£0.18. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.057 next year compared to a net loss per share of €0.073 last year. Breakeven Date Change • Jun 11
Forecast to breakeven in 2025 The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 42% per year to 2024. The company is expected to make a profit of €2.00m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule. Announcement • Jun 05
Directa Plus Plc, Annual General Meeting, Jun 27, 2024 Directa Plus Plc, Annual General Meeting, Jun 27, 2024. Location: 7th floor, 50 broadway, sw1h 0db, london United Kingdom New Risk • Apr 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (UK£13.5m market cap, or US$16.8m). Announcement • Feb 27
Directa Plus Plc (AIM:DCTA) signed a conditional share sale purchase agreement to acquire additional 48.96% stake in S.C. SetCar S.A. from GVC Investment Company Limited for €1.5 million. Directa Plus Plc (AIM:DCTA) signed a conditional share sale purchase agreement to acquire additional 48.96% stake in S.C. SetCar S.A. from GVC Investment Company Limited for €1.5 million on February 26, 2024. The Consideration is structured as an immediate payment of €0.5 million, which has been paid from Directa's existing cash resources, and a further payment of €1.0 million, which is due prior to March 30, 2024. For the year ended December 31, 2023, Setcar has reported revenues of €7.66 million, EBITDA of €0.35 million and net assets of €2.7 million. The completion of the acquisition is conditional on, inter alia, the payment of total consideration of €1.5 million and the passing of certain resolutions by the shareholders of Setcar at a shareholder meeting expected to be held in April 2024. Neil McDonald and Adam Rae of Cavendish Capital Markets Limited acted as financial advisor to Directa Plus. Announcement • Feb 13
Directa Plus plc Provides Earnings Guidance for the Year Ended 31 December 2023 Directa Plus Plc provided earnings guidance for the year ended 31 December 2023. For the year, the company expects to report revenues of c. €11 million. New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (UK£12.6m market cap, or US$15.8m). New Risk • Dec 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.9m net loss next year). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (UK£19.8m market cap, or US$25.0m). Reported Earnings • Sep 28
First half 2023 earnings released: €0.028 loss per share (vs €0.034 loss in 1H 2022) First half 2023 results: €0.028 loss per share (improved from €0.034 loss in 1H 2022). Revenue: €4.59m (down 17% from 1H 2022). Net loss: €1.85m (loss narrowed 17% from 1H 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 5.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. New Risk • Sep 19
New major risk - Revenue and earnings growth Earnings have declined by 2.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£33.0m market cap, or US$40.9m). Breakeven Date Change • Sep 18
Forecast to breakeven in 2025 The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €3.80m in 2025. Average annual earnings growth of 85% is required to achieve expected profit on schedule. Announcement • Sep 08
Directa Plus Plc to Report First Half, 2023 Results on Sep 27, 2023 Directa Plus Plc announced that they will report first half, 2023 results on Sep 27, 2023 Announcement • Jun 29
Directa Plus Receives Two New Italian Patents Directa Plus has been granted two new Italian patents, the EP patent, which relates to the 'apparatus for treating materials with plasma', and the ET patent, which relates to the 'composition comprising graphene for the treatment of textile articles'. These new grants represent a step forward in Directa Plus' intellectual property strategy and protects the Company's unique production process and the evolution of its graphene technology. Following the grant of the two patents, Directa Plus' IP portfolio now comprises of 22 patent families, with 84 patents granted and 38 patents pending. EP patent: Covers the apparatus for treating materials with plasma, in particular a device comprising a plasma microwave generator, a waveguide, and a microwave system torch, suitable for generating and sustaining atmospheric thermal plasma for treating powder materials. This is key to the Group's IP strategy as plasma technology sits at the core of Directa Plus' unique production process and is what distinguishes the Company from its competitors. Through its plasma technology, Directa Plus generates super-expanded graphite (Grafysorber®) with unique properties and performances in a chemical-free process. The EP patent is the technical evolution of the patent for 'production of nano-structures', and covers all the engineering improvements made to the plasma system to enhance the performance of the technology in terms of yields and the quality of the super expanded graphite obtained. The patent priority date is 19 December 2018. ET Patent: Covers the composition for treating textile articles and is a further evolution of the use of G+ in textiles, expanding the Group's patent coverage in textile applications. It covers a 100% natural and environmentally sustainable printing paste enhanced by graphene's antimicrobial, electrical and thermal conductivity properties. The patent also protects textile articles treated with the composition, including manufactured products for personal health protection. The natural make-up of this composition firmly aligns with Directa Plus' focus on sustainability and environmental protection. The patent priority date is the 4 May 2021. Announcement • Jun 09
Directa Plus plc Announces the Launch of New Product, GRAPHITO Directa Plus announced the launch of a new product, GRAPHITO, in collaboration with Candiani Denim (Candiani), an international textile producer based in Italy, focused on innovation and sustainability. GRAPHITO is an eco-denim textile and represents a significant advancement in the sustainable fashion industry by addressing denim's environmental impact and extending the lifespan of denim garments. GRAPHITO comprises of Directa Plus' patented technology, Graphene, which enhances a fabric with antimicrobial and thermal properties, along with Candiani Denim's bio-based polymer, Kitotex, which replaces liquid plastic (PVA) in textile production processes, making GRAPHITO denim unique and unrivalled. The enhanced properties of the material will see a significant reduction in water usage, energy consumption and carbon emissions of up to 75% in the garment's wash lifecycle, as the material's antibacterial and antiviral properties allows for up to 10 wear per lifecycle. Graphene's thermoregulating properties also make it a cross-seasonal denim fabric. The launch of GRAPHITO denim marks a significant milestone in the quest for eco-friendly fashion, offering consumers a premier denim choice that combines style, performance, and a reduced environmental footprint. GRAPHITO denim is launching in Candiani Denim's store in Milan, Italy. Candiani was founded in 1934 and has grown to become one of the world's most sustainable denim factories, creating premium fabrics, using eco-friendly techniques. Candiani supplies and partners with some of the world's best known fashion brands, including Hugo Boss, Stella Paul, and Steve Aoki. Announcement • May 20
Directa Plus Plc, Annual General Meeting, Jun 15, 2023 Directa Plus Plc, Annual General Meeting, Jun 15, 2023, at 14:00 Coordinated Universal Time. Location: 7th Floor, 50 Broadway London United Kingdom Reported Earnings • May 12
Full year 2022 earnings released: €0.07 loss per share (vs €0.06 loss in FY 2021) Full year 2022 results: €0.07 loss per share (further deteriorated from €0.06 loss in FY 2021). Revenue: €11.3m (up 31% from FY 2021). Net loss: €4.82m (loss widened 32% from FY 2021). Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Price Target Changed • May 12
Price target decreased by 15% to UK£1.78 Down from UK£2.10, the current price target is provided by 1 analyst. New target price is 147% above last closing price of UK£0.72. Stock is down 33% over the past year. The company posted a net loss per share of €0.07 last year. Announcement • Nov 21
Directa Plus plc Announces Directorate Change Directa Plus announce the appointment of Sarah Cope as a Non-executive director. Sarah has over 20 years' experience as an investment banker in London, advising small and mid-sized companies on corporate governance, strategy, amalgamations and disposals, capital markets and regulatory compliance. She has predominantly advised AIM listed companies in the Oil and Gas sector, assisting publicly traded companies to raise finance for their exploration, development and production projects around the world. Following this appointment, Neil Warner has stepped down from the Board. As a consequence, Sarah will be nominated to take over from Neil as the Chair of the Audit Committee. Price Target Changed • Nov 16
Price target increased to UK£2.10 Up from UK£1.22, the current price target is an average from 2 analysts. New target price is 150% above last closing price of UK£0.84. Stock is down 45% over the past year. The company posted a net loss per share of €0.06 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Interim Independent Non-Executive Chairman Richard Hickinbotham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 18
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Interim Independent Non-Executive Chairman Richard Hickinbotham was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 17
Directa Plus plc Appoints General Wesley K. Clark, as Non-Executive Director Directa Plus Plc announce the appointment of General Wesley K. Clark, (US Army ret.) as a Non-Executive Director. Wesley K. Clark is a businessman, educator, and writer, with wide experience in sectors including energy, oil and gas, biofuels, electric power and batteries and his experience and skill are aligned with the Company's strategic ambitions in the North American market. General Clark, a US national, is Chairman and CEO of Wesley K. Clark & Associates, a strategic consulting firm, Chairman and Founder of Enverra Inc., a licensed investment bank, and Chairman of Energy Security Partners, LLC. In the not-for-profit space, he is a Senior Fellow at UCLA's Burkle Center for International Relations and a Director of the Atlantic Council. A best-selling author, General Clark has written four books and is a frequent contributor to TV and to news media. Wesley Clark retired as a four-star general after 38 years in the United States Army, having served in his last posts as Commander of US Southern Command and then as Commander of US European Command/Supreme Allied Commander, Europe. He graduated first in his class at West Point and completed degrees in Philosophy, Politics and Economics at Oxford University (B.A. and M.A.) as a Rhodes scholar. He also worked with Ambassador Richard Holbrooke in the Dayton Peace Process, where he helped write and negotiate significant portions of the 1995 Dayton Peace Agreement. In his final assignment as Supreme Allied Commander Europe he led NATO forces to victory in Operation Allied Force, a 78-day air campaign, backed by ground invasion planning and a diplomatic process, saving 1.5 million Albanians from ethnic cleansing. His awards include the Presidential Medal of Freedom, Defense Distinguished Service Medal (five awards), Silver Star, Bronze Star, Purple Heart, honorary knighthoods from the British and Dutch governments, and numerous other awards from other governments, including the award of Commander of the Ordre National de la Légion d'honneur. He has also been awarded the Department of State Distinguished Service Award and numerous honorary doctorates. Following this appointment, David Gann has stepped down from the Board. Reported Earnings • Sep 30
First half 2022 earnings released: €0.03 loss per share (vs €0.024 loss in 1H 2021) First half 2022 results: €0.03 loss per share (further deteriorated from €0.024 loss in 1H 2021). Revenue: €5.61m (up 42% from 1H 2021). Net loss: €2.23m (loss widened 51% from 1H 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 8.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Breakeven Date Change • Sep 29
Forecast to breakeven in 2023 The 2 analysts covering Directa Plus expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €200.4k in 2023. Average annual earnings growth of 103% is required to achieve expected profit on schedule. Announcement • Sep 02
Directa Plus Plc to Report First Half, 2022 Results on Sep 29, 2022 Directa Plus Plc announced that they will report first half, 2022 results on Sep 29, 2022 Announcement • Aug 30
Directa Plus Plc Provides US Patent Notice Directa Plus announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for the grant of a patent covering the Company's G+® embedded polyurethane membrane, developed explicitly for the textile industry, together with its production method and its applications. The patent, titled "Polyurethane film comprising graphene and preparation process thereof", has apriority date of 5 May 2017. The official grant, expected shortly, will follow on from the completion of the filing process. G+® membranes are highly functional membranes that combine breathability and water protection with thermal and electrical conductivity. They provide superior thermal comfort by enhancing heat retention, due to high infrared absorption, while equalising it as a result of high in-plane thermal conductivity. They are electrically conductive, and the conductivity properties can be adjusted to confer antistatic behaviours for heating. Directa Plus' G+® membranes are non-toxic, non-cytotoxic, and safe against the skin. The membranes are used in apparel markets including the sportswear, workwear, military, luxury and accessories segments. In addition, they are being developed for use in the automotive, filtration and upholstery markets. Following the official grant of the patent, Directa Plus's IP portfolio will comprise 20 patent families with 80 patents granted and 30 patents pending. Major Estimate Revision • Jul 07
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €14.0m to €14.2m. Forecast EPS reduced from -€0.01 to -€0.04 per share. Chemicals industry in the United Kingdom expected to see average net income growth of 29% next year. Consensus price target of UK£2.53 unchanged from last update. Share price was steady at UK£0.99 over the past week. Announcement • Jun 22
Directa Plus Plc Grants Italian Filtration Patent Directa Plus announced that the Company has been granted an Italian patent covering the use of the Company's G+® pristine graphene nanoplatelets applied totextile substrates for high bacterial filtration efficiency media for filtration applications. The priority date for the patent is 25 May 2020. G+® applied to textile substrates provides proven antibacterial and antiviral (including anti-SARS-CoV-2) performance. The target filtration market applications cover both medical and industrial use. Directa Plus started work on air filtration in 2020 with a signature project that successfully supplied face masks with anti-SARS-CoV-2 protection. This work led quickly into exploring industrial filtration applications starting with the automotive and HVAC (heating, ventilation and air conditioning) markets. Directa Plus, as already announced, has partnered with a leading worldwide supplier of non-woven textile materials to develop a suite of new products for automotive and industrial applications based on the antimicrobial properties (antibacterial and antiviral), thermal comfort and electrical conductivity properties of G+® enhanced fabrics. Following the grant of the patent, Directa Plus's IP portfolio comprises 20 patent families with 73 patents granted and 28 patents pending. Announcement • Jun 18
Directa Plus plc Announces Executive Changes Directa Plus announced that Sir Peter Middleton will step down as Chairman following the Meeting, which is in line with his intention to step down announced on the 19 May 2022. Richard Hickinbotham has been appointed interim Chairman. The Board of Directors is committed to an immediate process of consultation to review and refresh the constitution of the Board, in particular to bring additional diversity and expertise to the Company. Announcement • May 20
Directa Plus Plc, Annual General Meeting, Jun 17, 2022 Directa Plus Plc, Annual General Meeting, Jun 17, 2022, at 09:30 Coordinated Universal Time. Location: at 11-12 St. James's Square London United Kingdom Reported Earnings • May 06
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: €0.06 loss per share (up from €0.069 loss in FY 2020). Revenue: €9.45m (up 47% from FY 2020). Net loss: €3.65m (loss narrowed 13% from FY 2020). Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 23%. Over the next year, revenue is forecast to grow 42% compared to a 17% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year. Price Target Changed • Apr 27
Price target increased to UK£2.38 Up from UK£1.22, the current price target is an average from 2 analysts. New target price is 98% above last closing price of UK£1.20. Stock is up 4.3% over the past year. The company is forecast to post a net loss per share of €0.049 next year compared to a net loss per share of €0.069 last year. Announcement • Apr 04
Directa Plus Receives Authorisation from the United States Environment Protection Agency Directa Plus announced that it has received authorisation from the United States Environment Protection Agency for the Company's Grafysorber® technology to be used on any oil contamination on US territory. Directa Plus's patented Grafysorber® technology is a graphene-based solution for treating water sludges and emulsions containing hydrocarbons and is at least five times more effective than current technologies - adsorbing more than 100 times its own weight of oil-based pollutants. In addition, Grafysorber® is sustainably produced, non-flammable and reusable, with the adsorbed hydrocarbons recoverable. The approval follows a first presentation of the technology to the California Natural Resource Agency, the highest Californian environmental authority, which suggested that Directa Plus undertook the authorization process with the US Federal Environmental Protection Agency (EPA) to allow the use of Grafysorber® in the United States. After a full review of the information provided by Directa Plus, the US EPA has issued an official authorization letter stating that Grafysorber® fully meets the EPA's legal requirements and can be used at any oil spill on US territory. Board Change • Dec 31
High number of new directors CFO & Director Giorgio Bonfanti was the last director to join the board, commencing their role in 2021. Reported Earnings • Oct 01
First half 2021 earnings released: €0.024 loss per share (vs €0.038 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €3.95m (up 41% from 1H 2020). Net loss: €1.48m (loss narrowed 36% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 19
Full year 2020 earnings released: €0.07 loss per share (vs €0.068 loss in FY 2019) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: €6.78m (up 158% from FY 2019). Net loss: €4.20m (loss widened 17% from FY 2019). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 28
Directa Plus plc Announces Positive Advances in Its Research into Printing Graphene-Based Inks Onto Textiles Directa Plus Plc announced positive advances in its research into printing graphene-based inks onto textiles. Since two years Directa has been working with an International Textile Group to develop new G+ graphene printing technique for the textile market and in April 2021 for the first time a G+ graphene-based ink, which used a specific grade of graphene developed for the purpose, has been digitally jetted. This is a preliminary result but it proves the feasibility of the technology and is a very important milestone for Directa's product development strategy in the textile vertical. Executive Departure • Apr 03
Executive Director has left the company On the 31st of March, Marco Ferrari's tenure as Executive Director ended after 4.9 years in the role. As of December 2020, Marco personally held 52.55k shares (UK£43k worth at the time). Marco is the only executive to leave the company over the last 12 months. Announcement • Mar 18
Directa Plus Plc Provides Revenue Guidance for the First Quarter of Fiscal 2021 Directa Plus Plc provided revenue guidance for the first quarter of fiscal 2021. The company announced trading in first quarter of 2021 has been strong, with revenues expected to be around €1.8 million, up 20% from the same period in 2020 (€1.5 million). Announcement • Mar 10
Directa Plus plc Announces Successful Absorption Evaluation Test Directa Plus announced that it has received another positive test result relating to the potential for absorption of the Company's pristine graphene nanoplatelets powder (Pure G+®) through human skin. This latest in vitro test showed that there is no absorption potential for Pure G+®, taking the total number of positive in vitro test results to eight. The study was carried out by an independent third party and followed the standards of OECD 428 ("In vitro evaluation of the absorption potential of a product throughout reconstructed human epidermis"). The purpose of the test was the evaluation of the skin absorption potential of Pure G+® through an in vitro reconstructed human epidermis. Pure G+ was applied on the tissue surface for six and 24 hours and at the end of the experimental time, a calculation of the quantity of Pure G+® graphene that had penetrated through the epidermis was performed. The acquisition of further successful results from in vitro tests of the Company's hypoallergenic, non-toxic products is vital for their use in textile markets where customers have to be certain of the safety of the apparel they produce and market. Announcement • Feb 23
Directa Plus plc Signs Supply Agreement and A Strategic R&D Agreement with Nextech Batteries Inc Directa Plus Plc announce that the company has signed a supply agreement and a Strategic R&D Agreement with NexTech Batteries Inc. ("NexTech"), a leading company in the field of Lithium Sulphur ("Li-S") batteries based in Nevada, US. These agreements follow on from the Memorandum of Understanding entered into between the two companies and announced on 26 October 2020. The Supply Agreement has an initial duration of three years, with an option to extend for an additional two years by mutual agreement and governs the provision of a specific grade of G+® pristine graphene nanoplatelets by Directa Plus to NexTech for the production of the active materials of the cathode in NexTech's first generation of Li-S batteries. Under the Supply Agreement, Directa Plus will supply NexTech with 300kg of nanoplatelets in 2021, with quantities for delivery in each subsequent year to be agreed between the parties at the end of each year and subject to the achievement of order quantities related to NexTech's anticipated growth. Directa Plus and NexTech have also agreed a worldwide bilateral exclusivity between the parties in the lithium battery field for the duration of the Supply Agreement. The R&D Agreement, also with a duration of three years, provides for Joint Lab activities with the intention of developing new specific grades of G+® graphene nanoplatelets for a next generation of Li-S batteries. Both parties will dedicate selected scientists from their R&D teams and part of their respective facilities to the enterprise. Is New 90 Day High Low • Feb 04
New 90-day high: UK£0.97 The company is up 55% from its price of UK£0.63 on 05 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. Is New 90 Day High Low • Jan 15
New 90-day high: UK£0.93 The company is up 36% from its price of UK£0.68 on 16 October 2020. The British market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. Is New 90 Day High Low • Nov 23
New 90-day high: UK£0.92 The company is up 12% from its price of UK£0.82 on 25 August 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Nov 02
New 90-day low: UK£0.65 The company is down 15% from its price of UK£0.76 on 04 August 2020. The British market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Oct 12
New 90-day low: UK£0.69 The company is down 4.0% from its price of UK£0.72 on 14 July 2020. The British market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 